Podcast: Embed

Subscribe: Apple Podcasts | Spotify | Amazon Music | Android | Pandora | iHeartRadio | TuneIn | Deezer | RSS

“To study the phenomena of disease without books is to sail an uncharted sea, while to study books without patients is not to go to sea at all.” – Sir William Osler. CardioNerds thank the patients and their loved ones whose stories teach us the Art of Medicine and support our Mission to Democratize Cardiovascular Medicine.

Enjoy this Circulation 2022 Paths to Discovery article to learn about the CardioNerds story, mission, and values.

US Cardiology Review is now the official journal of CardioNerds! Submit your manuscript here.

---

Pearls

1. The combination of low voltage on ECG and increased wall thickness on echocardiogram should always raise suspicion for an infiltrative cardiomyopathy, not hypertensive heart disease.
2. A negative SPEP does not exclude a plasma cell dyscrasia; serum free light chains and urine immunofixation are required, and PYP should only be used to support a noninvasive ATTR diagnosis after a monoclonal process has been excluded.
3. Nearly one in four ATTR patients have a coexisting MGUS, making serum markers alone insufficient to distinguish AL from ATTR; when cardiac involvement is suspected, endomyocardial biopsy remains the gold standard for confirming amyloid deposition.
4. Preload dependence and low stroke volume in cardiac amyloidosis create extreme sensitivity to volume shifts and positional changes, requiring a much narrower margin of safety than typical heart failure.
5. In advanced cardiac AL amyloidosis, delays in initiating anti-plasma cell therapy can rapidly narrow the therapeutic window, making urgent multidisciplinary coordination essential.

Notes

Notes were drafted by Dr. Flavia Tejada Frisancho, Dr. Ahmad Ahmad and Dr. Blanca Simon Frances.

1. What clinical features should raise suspicion for cardiac amyloidosis in a patient presenting with heart failure?

• Cardiac amyloidosis should be considered when the clinical picture does not behave like typical hypertensive, ischemic, or dilated cardiomyopathy. In this case, the key clue was pattern recognition: new heart failure, rapid progression, low-voltage ECG, severe concentric LV thickening, small LV cavity, biventricular dysfunction, renal dysfunction, pleural effusions, and abnormal light chains. 
• Shared cardiac red flags include increased LV wall thickness out of proportion to hypertension or valvular heart disease, diastolic dysfunction, biatrial enlargement, restrictive filling physiology, biventricular involvement, atrial fibrillation or conduction disease, elevated natriuretic peptides and troponin out of proportion to symptoms, and intolerance of standard heart failure therapies. 
• Extracardiac manifestations can provide important clues and include proteinuria, peripheral or autonomic neuropathy, bilateral carpal tunnel syndrome, lumbar spinal stenosis, and spontaneous biceps tendon rupture. 
• AL-predominant clues include rapid clinical progression over weeks to months, fatigue, weight loss, nephrotic-range proteinuria or renal dysfunction, pleural effusions, hypotension or shock physiology, low-voltage ECG, and evidence of a monoclonal protein or abnormal serum free light chains. 
• Pathognomonic extracardiac findings for AL amyloidosis include macroglossia, periorbital purpura, and acquired factor X deficiency. 
• ATTR-predominant clues often evolve over years and include bilateral carpal tunnel syndrome, lumbar spinal stenosis, spontaneous biceps tendon rupture, aortic stenosis, and HFpEF with increased wall thickness. Low-voltage ECG can occur but is less common in ATTR than AL. 
• The key bedside teaching point is to lean into the inconsistency. Hypertension can cause LVH, but hypertension does not fully explain low voltage, rapid biventricular failure, renal dysfunction with monoclonal light chains, pleural effusions, and severe hemodynamic fragility. 

---

2. Once cardiac amyloidosis is suspected, how should we approach the diagnosis?

• The diagnostic approach begins with suspicion and then immediately separates two pathways:
  • rule out AL amyloidosis 
  • evaluate for ATTR amyloidosis

3. Why is it so important to rule out AL amyloidosis early?

• AL amyloidosis is both a hematologic and cardiac emergency. 
• The underlying plasma cell clone produces misfolded immunoglobulin light chains that:
  • deposit as amyloid fibrils 
  • exert direct cardiotoxic effects on cardiomyocytes 
• Light chains impair lysosomal function, disrupt autophagy, increase oxidative stress, and contribute to progressive cellular injury and death. 
• Cardiac involvement is the primary determinant of prognosis in AL amyloidosis. 
• Risk stratification commonly incorporates:
  • troponin 
  • NT-proBNP 
  • serum free light chain burden 
• Mayo staging systems use these biomarkers to estimate prognosis and identify patients at especially high early mortality risk. 
• Patients with advanced cardiac involvement can deteriorate over days to weeks, particularly when there is hypotension, markedly elevated NT-proBNP, elevated troponin, renal dysfunction, low output physiology. 
• Early hematology involvement is essential because treatment targets the plasma cell clone. 
• Daratumumab combined with bortezomib, cyclophosphamide, and dexamethasone (D-VCd) is now considered standard first-line therapy for newly diagnosed AL amyloidosis. 
• The addition of daratumumab has been associated with deeper, faster responses, improved organ outcomes and improved survival. 
• Treatment logistics matter. In advanced cardiac AL amyloidosis, delaying therapy until outpatient follow-up may be dangerous if the patient is unstable or has high-risk features. 
• The practical takeaway:
  • once AL is suspected, do not wait for every outpatient test to return before escalating care.
  • send the full monoclonal protein workup.
  • involve hematology and amyloid specialists early.
  • expedite tissue diagnosis and treatment planning.

---

4. How does cardiac amyloidosis affect hemodynamics and response to therapy?

• Amyloid infiltration produces restrictive cardiomyopathy characterized by: impaired ventricular compliance, elevated right- and left-sided filling pressures, low stroke volume, preload dependence, afterload intolerance, and limited ability to augment cardiac output.
• Because stroke volume is fixed, heart rate becomes an important contributor to cardiac output. Beta blockers, non-dihydropyridine calcium channel blockers, and aggressive vasodilators may be poorly tolerated, particularly in AL cardiac amyloidosis with hypotension or advanced restrictive physiology.
• Patients may appear profoundly volume overloaded while remaining severely forward-flow limited. This explains why diuresis can be difficult until perfusion improves, and why inotropes may produce a dramatic improvement in urine output in selected patients with low-output physiology.

• Right heart catheterization can help characterize the physiology. In this case, invasive hemodynamics showed elevated filling pressures and pulmonary hypertension due to left-sided disease: RA 12 mmHg, PA 58/26 mmHg, mean PA 39 mmHg, PCW 20 mmHg, and cardiac index approximately 2.2-2.3 L/min/m2.
• Positioning and respiratory mechanics matter. In this case, lying supine during renal ultrasound likely worsened respiratory mechanics in the setting of large pleural effusions and restrictive physiology, contributing to hypoxia and PEA arrest. 

This case highlights how patients with cardiac amyloidosis can be extremely hemodynamically fragile.

---

5. What management principles are important once AL cardiac amyloidosis is suspected or confirmed?

• Management requires multidisciplinary coordination among Advanced Heart Failure, Hematology/Oncology, Nephrology, Critical Care, Pathology, and, when needed, amyloid specialty clinics.
• Supportive heart failure therapy centers on careful volume management. Loop diuretics are often needed, sometimes with sequential nephron blockade, but the margin between congestion and underfilling is narrow due to preload dependence. 
• Guideline-directed medical therapy for conventional HFrEF may be limited by hypotension, renal dysfunction, low stroke volume, and autonomic dysfunction. The goal is not to force standard HFrEF therapy when the physiology does not support it.
• Pleural effusions may be large and recurrent. Drainage can improve respiratory mechanics, but it does not treat the underlying restrictive cardiomyopathy or plasma cell disorder.
• For AL amyloidosis, definitive therapy targets the plasma cell clone. Cardiac stabilization and chemotherapy planning must proceed in parallel, because ongoing light-chain production can drive rapid organ injury even after temporary hemodynamic improvement.
• The major clinical pearl from this case is that AL cardiac amyloidosis should be approached with the urgency of both advanced heart failure and an aggressive hematologic malignancy. Early recognition and expedited evaluation can be life-saving.

Media

References

1. Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure. J Am Coll Cardiol. 2022;79(17):e263-e421.
2. Kittleson MM, Maurer MS, Ambardekar AV, et al. Cardiac amyloidosis: evolving diagnosis and management: a scientific statement from the American Heart Association. Circulation. 2020;142(1):e7-e22.
3. Writing Committee, Kittleson MM, Ruberg FL, et al. 2023 ACC expert consensus decision pathway on comprehensive multidisciplinary care for the patient with cardiac amyloidosis. J Am Coll Cardiol. 2023;81(11):1076-1126.
4. Garcia-Pavia P, Rapezzi C, Adler Y, et al. Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC Working Group on Myocardial and Pericardial Diseases. Eur Heart J. 2021;42(16):1554-1568.
5. Falk RH, Quarta CC, Dorbala S. How to image cardiac amyloidosis. Circ Cardiovasc Imaging. 2014;7(3):552-562.
6. Felker GM, Boehmer JP, Hruban RH, et al. Echocardiographic findings in fulminant and acute myocarditis. J Am Coll Cardiol. 2000;36(1):227-232.
7. Ioannou A, Massa P, Patel RK, et al. Conventional heart failure therapy in cardiac ATTR amyloidosis. Eur Heart J. 2023;44(31):2893-2907.
8. Palladini G, Merlini G. How I treat AL amyloidosis. Blood. 2022;139(19):2918-2930.
9. Dorbala S, Ando Y, Bokhari S, et al. ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis. J Card Fail. 2019;25(11):e1-e39.
10. Gillmore JD, Maurer MS, Falk RH, et al. Nonbiopsy diagnosis of cardiac transthyretin amyloidosis. Circulation. 2016;133(24):2404-2412.
11. Dispenzieri A, Gertz MA, Kyle RA, et al. Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis. J Clin Oncol. 2004;22(18):3751-3757. [Mayo 2004 staging]
12. Kumar S, Dispenzieri A, Lacy MQ, et al. Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements. J Clin Oncol. 2012;30(9):1055-1062. [Mayo 2012 staging]
13. Kastritis E, Leleu X, Arnulf B, et al. Daratumumab-based treatment for immunoglobulin light-chain amyloidosis (ANDROMEDA): a randomised, phase 3 trial. Lancet. 2021;397(10292):2337-2347.
14. Martens P, Bhattacharya S, Longinow J, et al. Hemodynamic profiling and prognosis in cardiac amyloidosis. Circ Heart Fail. 2023;16(3):e010078.
15. Porcari A, Fontana M, Gillmore JD. Transthyretin cardiac amyloidosis. Cardiovasc Res. 2023;118(18):3517-3535.
16. Ruberg FL, Maurer MS. Cardiac amyloidosis due to transthyretin protein: a review. JAMA. 2024;331(9):778-791.
17. Ikura H, Endo J, Kitakata H, Moriyama H, Sano M, Fukuda K. Untangling amyloidosis: recent advances in cardiac amyloidosis. Korean Circ J. 2022;52(10):725-742.
18. Larsen SB, Ladefoged B, Pedersen ALD, et al. Changes of clinical characteristics, distribution of red flags and prognosis in contemporary patients with wild-type transthyretin amyloidosis cardiomyopathy. Ann Med. 2024;56(1):2398735.
19. Transthyretin Cardiac Amyloidosis Evaluation and Management: 2025 ACC Concise Clinical Guidance. J Am Coll Cardiol. 2025. doi:10.1016/j.jacc.2025.09.004.